Pharmaceutical compositions containing carvedilol and hydrochlorothiazide

Abstract

A pharmaceutical combination preparation for the treatment of cardiac and cardiovascular disorders, such as hypertension, angina pectoris, cardiac insufficiency and illnesses associated therewith, contains the active substances carvedilol, or a pharmaceutically acceptable salt thereof, and hydrochlorothiazide, or a pharmaceutically acceptable salt thereof, as well as pharmaceutically usual additives.

What is claimed is:  
     
         1 . A tablet which comprises (i) carvedilol or a pharmaceutically acceptable salt thereof, (ii) hydrochlorothiazide or a pharmaceutically acceptable salt thereof, and (iii) at least one pharmaceutically acceptable additive.  
     
     
         2 . The tablet of  claim 1 , wherein the weight ratio of to (i) hydrochlorothiazide or a pharmaceutically acceptable salt thereof, to (ii) carvedilol or a pharmaceutically acceptable salt thereof, is between about 1:0.5 and about 1:10.  
     
     
         3 . The tablet of  claim 1 , wherein the tablet comprises (i) about 10 mg to about 50 mg of carvedilol or a pharmaceutically acceptable salt thereof, and (ii) about 5 mg to about 30 mg hydrochlorothiazide or a pharmaceutically acceptable salt thereof.  
     
     
         4 . The tablet of  claim 1 , wherein the at least one pharmaceutically acceptable additive comprises a binder, disintegrant, glidant, adsorption agent, separating agent, filler, or carrier.  
     
     
         5 . The tablet of  claim 1 , wherein the tablet comprises from about 0% to about 50 % by weight lactose, from about 0% to about 50% by weight saccharose, from about 0% to about 10% by weight magnesium stearate, from about 0% to about 30% by weight cellulose, from about 0% to about 10% by weight polyvinylpyrrolidone, from about 0% to about 10% by weight polymeric cellulose compounds, from about 0% to about 10% by weight silicon dioxide, and from about 0% to about 20% by weight cross-linked polyvinylpyrrolidone.  
     
     
         6 . The tablet of  claim 5 , wherein the tablet comprises about 25 mg carvedilol and about 12.5 mg hydrochlorothiazide.  
     
     
         7 . The tablet of  claim 6 , wherein the tablet comprises about 25 mg carvedilol, about 12.5 mg hydrochlorothiazide, about 28.06 mg lactose monohydrate, about 25 mg saccharose, about 2.17 mg magnesium stearate, about 10 mg microcrystalline cellulose, about 1.78 mg polyvinylpyrrolidone (25,000), about 5.32 mg silicon dioxide, and about 20.17 mg cross-linked polyvinylpyrrolidone.